Botulinum neurotoxin type A inhibits the release of acetylcholine from cholinergic motor and autonomic nerves. Intramuscular injection leads to muscle relaxation, and intradermal injection reduces sweat gland secretion. The recommended dose depends on which preparation of botulinum toxin type A is used and its dilution, the size of the muscle or gland being injected, and the method used to localise the injection site. Repeat doses are usually required as the effect of the toxin wears off after 3-4 months. Therapy including stretching, splinting and strengthening may prolong the effect of muscle relaxation. Realistic goal setting before treatment is vital.
Introduction
Botulinum neurotoxin was first identified in 1897 and is a product of Clostridium botulinum, an anaerobic bacterium which causes botulism food poisoning. During the 1940s, botulinum toxin type A was purified and isolated in a crystalline form. In 1989 the US Food and Drug Administration (FDA) approved botulinum toxin type A for the treatment of strabismus, blepharospasm and hemifacial spasm. It has since been approved for cervical dystonia, hyperhidrosis and cosmetic use. There are now over 30 conditions in which botulinum toxin type A has been reported to be of benefit.
mechanism of action
Botulinum neurotoxin type A blocks neuromuscular conduction by inhibiting the release of acetylcholine from motor or autonomic nerve terminals. Injected intramuscularly, it produces a localised chemical denervation of the muscle, resulting in localised muscle weakness or paralysis. When injected intradermally, the toxin produces chemical denervation of sweat glands and reduces local sweating. The denervation is reversible.
Nerve endings recover over three or more months during which muscle tone increases and glandular secretion recommences.
Botulinum toxin products
There are two different preparations of the type A toxin commercially available in Australia; these are a purified neurotoxin complex (Botox) and a haemagglutinin complex (Dysport). They are dispensed in vials as a vacuum dried powder which is reconstituted with sterile normal saline. Once opened, vials should be stored in the refrigerator and used within 24 hours. The potencies of both preparations are expressed as units of activity, which relate to the median lethal dose in mice.
The biological activity for each preparation is unique, so one unit of the neurotoxin complex is not equal to one unit of the haemagglutinin complex. As the potency and safety of these products differ, dose finding on a case by case basis may be necessary if both products are used in the same patient.
Another botulinum toxin type A product (Xeomin) is formulated without complexing proteins and has been approved for use in several European countries but not in Australia. It has recently been shown to be of benefit for focal dystonia and spasticity.
Botulinum toxin type B (Myobloc) is rarely used in Australia.
It has been reported to be beneficial in adults with cervical dystonia who have developed resistance to botulinum toxin type A. 1 
Clinical indications
Considering whether to start a patient on botulinum toxin depends on balancing the risks of treatment against the potential improvements in active and passive function, level of pain, secondary effects of unwanted muscle overactivity and quality of life. In Australia, specialist medical practitioners such as ophthalmologists, neurologists, surgeons, rehabilitation specialists and paediatricians may access the government's Section 100 scheme. This provides reimbursement for the cost of botulinum toxin type A for the following conditions: n blepharospasm n spasmodic torticollis n dynamic equinus foot deformity associated with cerebral palsy in children two years or over n spasticity following stroke.
Botox is also approved for the treatment of strabismus in children and adults, focal spasticity of the limbs, primary hyperhidrosis of the axillae, and spasmodic dysphonia. Botox Focal hand dystonia (writer's cramp) 4 Focal hand dystonia is a task-specific dystonia that may affect Spasmodic dysphonia (focal laryngeal dystonia) 6 Vocal cord spasm, typically adductor muscle spasm, may interfere with communication, and responds to botulinum toxin type A injections. Spasm of the abductor muscle also occurs but may be less responsive to botulinum toxin type A treatment.
Laryngoscopy and electromyography are needed for diagnostic evaluation and injection. Injection of laryngeal muscles should be avoided in patients requiring a general anaesthetic for elective surgery. 
Focal spasticity

Cosmetic use
Botulinum toxin type A is used for treating glabellar lines (corrugator or procerus muscles), crow's feet (lateral fibres of orbicularis oculi muscle), and forehead lines (frontalis muscle).
Other uses
Botulinum toxin type A has also been shown to be of clinical benefit for patients with Parkinson's disease by reducing jaw tremor and excess salivation. 13 It has been used to relieve sensory and motor symptoms associated with tics, Tourette's syndrome and restless legs syndrome, and for patients with migraine, drooling or neurogenic bladder.
Administration
Before injection the toxin is diluted, usually with 0.5−5 mL of saline per vial. The extent of dilution affects the spread of the toxin once injected and will vary depending on a number of factors including:
n the condition being treated n the size of the muscle being injected n the risk of spread beyond the muscle n the effect of previous injection courses n the methods used to determine the injection site.
There are several ways to localise the muscle or gland to be 
lack of response
Explanations may include inadequate dose, inappropriate muscle selection or injection site, underlying muscle changes (such as contracture), or neutralising antibodies to the toxin. As botulinum toxin type A is derived from foreign proteins, there is potential for the body to mount an immune response which may reduce the therapeutic benefit of treatment. To avoid this, botulinum toxin type A injections should be given at least three months apart.
Conclusion
Botulinum toxin is used for an increasingly wide range of clinical problems, principally related to muscle or sweat gland overactivity. The effect is temporary, lasting 3-6 months.
Adjunctive therapies such as stretching or strengthening of antagonist muscles may allow for more sustained functional improvements after the biological effect of the botulinum toxin has ceased. Adverse effects are uncommon and usually temporary, although more serious effects including generalised weakness and dysphagia have been reported.
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Self-test questions
The On reviewing the latest edition of Psychotropic Guidelines, it took me a while to determine which sections had undergone the 'major revision' promised on the Therapeutic Guidelines website. There has been a reorganisation of chapters, with the useful 'Getting to know your psychotropic drugs' still prominent in the guide. The large table in previous editions listing potential drug interactions has been omitted, so one has to look up individual medications for this information. Presumably many
